Name : Inscribe (INS)
INS Price : $0.015 -2.07%
Consensus Mechanism : Multi-chain Token
Volume: 406,744
Shariah Judgement
This feature only can be accessed by subscribed users.
Shariah Status :
Last Screening: Q2 2024
Legitimacy:
Project:
Token:
Reward:
Shariah
Legitimacy
People
Shariah Analysis
Project/Products | Use Case | Status |
---|---|---|
Use Case | Status |
---|---|
System | Status | Interpretation |
---|---|---|
Legitimacy Analysis
Details | Status | |
---|---|---|
Whitepaper | ||
Project |
People Analysis
Details | Status | |
---|---|---|
Team |
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Strong
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Neutral
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Overview
Inscribe (INS) has established itself as the leading protocol in the realm of data-embedded blockchain transactions, known as Inscriptions. Offering unparalleled ease of use and limitless possibilities, Inscribe operates seamlessly across a wide range of blockchain networks, including EVM blockchains, BRC20/CBRC20, Dogechain, Injective, and non-EVM chains. With its 0.1 version, Inscribe ensures effortless interaction with users' preferred networks, such as Bitcoin, Ethereum, Avalanche, ZkSync, Binance Smart Chain, Arbitrum, Base, Fantom, Gnosis, and Polygon. Inscribe's key features include unified liquidity, simplified user experience, and multichain compatibility, making Inscriptions accessible to everyone with a single click.
Whitepaper & Documents
Sharlife uses TradingView technology to present price information through charts. TradingView serves as a charting platform catering to a worldwide community of traders and investors. With robust support across browsers, desktops, and mobile applications, the platform offers exceptional access to real-time data such as Dow Futures and BTC USD Chart, as well as the latest news, financial reports, stock screener, and economic .
COMMENTS
0 Comments